Clinical Trial Update: Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 safety study of ipratropium bromide in chronic obstructive pulmonary disease has completed. The trial was sponsored by Boehringer Ingelheim.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED